Orchid Pharma Limited Latest Updates

Consolidated Q3 FY26 Performance For the quarter ended December 31, 2025, Orchid Pharma reported a consolidated Net Loss of ₹12.61 crore, compared to a profit of ₹20.78 crore in the same period last year. Total revenue for the quarter stood at ₹212.88 crore, a 5.7% year-on-year decline. The company attributed the dip to sharp pricing erosion in key antibiotic molecules and a lower contribution from higher-margin regulated markets. Global Roll-out of Enmetazobactam The company is currently focused on the commercial ramp-up of its New Chemical Entity (NCE), Cefepime-Enmetazobactam (marketed as Exblifep). While the drug is already being distributed in India through a partnership with Cipla, Orchid is expanding its footprint in Europe, with volumes in Spain and Italy growing significantly. Management is reportedly in advanced discussions with three major parties for U.S. licensing, aiming to close a deal by the end of March 2026. 7ACA Project and Backward Integration Work is on track for the mechanical completion of the company’s 7ACA (7-Aminocephalosporanic Acid) manufacturing project by September 2026. This project is part of the government's Production Linked Incentive (PLI) scheme and is designed to provide complete backward integration for cephalosporin antibiotics. Commercial production is expected to begin 1–2 quarters post-completion, which is intended to significantly reduce reliance on imported raw materials. Operational Resilience and Debt Despite the recent losses, the company maintains a controlled balance sheet with a total debt-to-equity ratio of approximately 0.14. To date, the company has drawn roughly ₹170 crore in debt for its 7ACA project out of a planned ₹450 crore. Management recently noted that while FY26 is a "transition year," they expect a gradual margin recovery toward 10% in FY27 as the regulated market mix improves.